Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/9345
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAydin, Merve Arslan-
dc.contributor.authorJanapatla, Rajendra Prasad-
dc.contributor.authorChen, Chyi-Liang-
dc.contributor.authorLi, Hsin-Chieh-
dc.contributor.authorSu, Lin-Hui-
dc.contributor.authorChiu, Cheng-Hsun-
dc.date.accessioned2024-12-19T05:00:27Z-
dc.date.available2024-12-19T05:00:27Z-
dc.date.issued2023-06-
dc.identifier.citationOriginal Articleen_US
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/9345-
dc.description.abstractAbstract Background/purpose: Serotype 3 has persisted to be an important cause of invasive pneumococcal disease in adults in the post-vaccine era. We aimed to investigate clinical and microbiological characteristics of Streptococcus pneumoniae serotype 3 infection in Taiwan and identify the risk factors associated with severe clinical outcome. Methods: A multicenter observational study was conducted to analyze serotype 3 isolates collected between 2012 and 2021. Demographics, comorbidities, and risk categories were statistically compared with clinical outcome. Antimicrobial susceptibility testing and multilocus sequence typing were performed. Results: A total of 146 isolates were collected, including 12 isolates regarded as colonizers. Among 134 infected cases, 54 (40.3%) were aged 65 and older. Mortality was significantly associated with diabetes mellitus, immunosuppression, immunodeficiency, high-risk status, and older age. Susceptibility rates were high to levofloxacin (98.9%), moxifloxacin (100%), vancomycin (100%), and ceftriaxone (97.3%). 25.3% (37/146) of the isolates showed intermediate susceptibility and 0.7% (1/146) showed resistance to penicillin. ST180 was the dominant seq Conclusions: Serotype 3 infection showed a high mortality rate, especially in patients with older ages and comorbidities. Although the incidence rates decreased during the COVID-19 pandemic, serotype 3 remained as an important cause of infection after the implementation of PCV13. Developing a more effective vaccine against serotype 3 and monitoring the antimicrobial-resistant sequence types are necessary.en_US
dc.language.isoen_USen_US
dc.publisherElsevier Taiwan LLCen_US
dc.subjectStreptococcus pneumoniaeen_US
dc.subjectSerotype 3en_US
dc.subjectMortalityen_US
dc.subjectPrognosisen_US
dc.subjectAntimicrobial susceptibilityen_US
dc.subjectSequence typeen_US
dc.titleMicrobiological and clinical characteristics of Streptococcus pneumoniae serotype 3 infection and risk factors for severe outcome: A multicenter observational studyen_US
dc.typeArticleen_US
Appears in Collections:VOL 56 NO 3 2023

Files in This Item:
File Description SizeFormat 
598-604.pdf842.85 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.